



GP/641

#4 GP  
64-26-99

Docket No. 3532-4000

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Hahn et al.  
Serial No. : 09/184,418                      Group Art Unit: 1641  
Filed : November 2, 1998                      Examiner: TO BE ASSIGNED  
For : REFERENCE CLONES AND SEQUENCES FOR NON-SUBTYPE B  
ISOLATES OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

**TRANSMITTAL LETTER**

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

APR 19 1999

Transmitted herewith is:

GROUP 1806

- 1) Return Receipt Postcard
- 2) Certificate of Mailing
- 3) Supplemental Information Disclosure Statement (2 copies)
- 4) INFORMATION DISCLOSURE CITATION  
FORM PTO-1449, including cited references


Applicants believe that no fee is due. However, if that is not the case, the Commissioner is hereby authorized to charge any fees which may be required for any one of these papers, or credit any overpayment to Deposit Account No. 13-4500, Order No. 3532-4000.

In the event that an extension of time is required, or which may be required in addition to that requested in a petition for an extension of time, the Commissioner is requested to grant a petition for that extension of time which is required to make this response timely and is hereby authorized to charge any fee for such an extension of time or credit any overpayment for an extension of time to Deposit Account No. 13-4500, Order No. 3532-4000. A DUPLICATE COPY OF THIS DOCUMENT IS ATTACHED.

Respectfully submitted,  
MORGAN & FINNEGAN, L.L.P.

Dated: April 12, 1999

By:

  
James P. Demers  
Registration No. 34,320

Mailing Address:  
MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800



PATENT  
Docket No. 3532-4000

**THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant(s) : Hahn et al.  
Serial No. : 09/184,418 Group Art Unit: 1641  
Filed : November 2, 1998 Examiner: TO BE ASSIGNED  
For : REFERENCE CLONES AND SEQUENCES FOR NON-SUBTYPE B ISOLATES  
OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

**CERTIFICATE OF MAILING (37 C.F.R. 1.8a)**

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

I hereby certify that the attached

- 1) Return Receipt Postcard
- 2) TRANSMITTAL LETTER (2 copies)
- 3) Supplemental Information Disclosure Statement (2 copies)
- 4) INFORMATION DISCLOSURE CITATION FORM PTO-1449, including cited references

(including any paper(s) referred to as being attached or enclosed) and this Certificate of Mailing are being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.

Dated: April 12, 1999

By: 

James P. Demers  
Registration No. 34,320

**CORRESPONDENCE ADDRESS:**

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile



PATENT

Docket No. 3532-4000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Hahn et al. Group Art Unit: 1641  
Serial No : 09/184,418 Examiner: TO BE ASSIGNED  
Filed : November 2, 1998  
For : REFERENCE CLONES AND SEQUENCES FOR NON-SUBTYPE B ISOLATES OF  
HUMAN IMMUNODEFICIENCY VIRUS TYPE 1

*Handwritten signature and date: 04-26-99*

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, D.C. 20231

Sir:

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, may be deemed to be pertinent to the above-identified application and are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed: \_\_\_\_\_
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application: \_\_\_\_\_
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. \_\_\_\_\_, filed \_\_\_\_\_.
4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Supplemental Information Disclosure Statement since it is being filed in compliance with:  
  - ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of the above-identified application or filing date of the continued prosecution application filed on \_\_\_\_\_; or
  - ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
  - ☒ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office Action on the merits, whichever event occurred last.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.

6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$240.00 is enclosed in payment of the fee.
- ☐ Charge the fee to Deposit Account No. 13-4500. Order No. \_\_\_\_\_.
- A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. ☐ one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
- b. ☐ the attached petition requesting consideration of this Information Disclosure Statement; and
- c. ☐ the fee due under 37 C.F.R. §1.17(i)(1) which is paid as set forth in paragraph 10 below.
8. ☐ A fee is due under 37 C.F.R. §1.17(i)(1) for this Information Disclosure Statement since it is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue;
- b. ☐ 37 C.F.R. §1.313(b)(5), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To withdraw Application From Issue.
- c. ☐ The fee due under 37 C.F.R. §1.17(i)(1) is paid as set forth in paragraph 10 below.
9. ☐ I hereby certify that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ I hereby certify that no item of information in the Information Disclosure Statement field herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after make reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. ☐ A check in the amount of \$130.00 is enclosed in payment of the fee due under C.F.R. §1.17(i)(1).
- ☐ Charge the fee due under C.F.R. §1.17(i)(1) to Deposit Account No. 13-4500. Order No. \_\_\_\_\_. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Assistant Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500. Order No. 3532-4000. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,


MORGAN & FINNEGAN, L.L.P.

By: 

James P. Demers  
Registration No. 34,320

Dated: April 12, 1999

MORGAN & FINNEGAN, L.L.P.  
345 Park Avenue  
New York, New York 10154  
(212) 758-4800  
(212) 751-6849 Facsimile



Examiner Initial	Isolate/Clone	GenBank Accession No.	Sequence in GenBank	GenBank Date <sup>1</sup>
<b>1</b>	<b>92RW009.6<sup>2</sup></b>	<b>U88823</b>	<b>complete</b>	<b>Nov. 8, 1997</b>
<b>2</b>	<b>92RW009.14</b>	<b>U08793</b>	<b>env, partial cds<sup>3</sup></b>	<b>Jul. 31, 1996</b>
<b>3</b>	<b>92RW009.2</b>	<b>U16220</b>	<b>env gp120</b>	<b>Feb. 5, 1998</b>
<b>4</b>	<b>92RW009.3</b>	<b>U16221</b>	<b>env gp120</b>	<b>Feb. 5, 1998</b>
<b>5</b>	<b>92RW009.4</b>	<b>U16222</b>	<b>env gp120</b>	<b>Feb. 5, 1998</b>
<b>6</b>	<b>92RW009</b>	<b>U13441</b>	<b>env, V1 V2 region, partial</b>	<b>Aug. 2, 1995</b>
<b>7</b>	<b>92RW009</b>	<b>U86545</b>	<b>gag, partial cds</b>	<b>Mar. 19, 1997</b>
<b>8</b>	<b>92NG003.1</b>	<b>U88825</b>	<b>complete</b>	<b>Nov. 8, 1997</b>
<b>9</b>	<b>92NG003.1</b>	<b>U13208</b>	<b>env, partial cds</b>	<b>Aug. 24, 1995</b>
<b>10</b>	<b>92NG083.2</b>	<b>U88826</b>	<b>complete</b>	<b>Nov. 8, 1997</b>
<b>11</b>	<b>93BR020.1</b>	<b>AF005494</b>	<b>complete</b>	<b>May 7, 1998</b>
<b>12</b>	<b>93BR020.17</b>	<b>U27401</b>	<b>env and nef genes, partial cds</b>	<b>Aug. 19, 1996</b>
<b>13</b>	<b>93BR020</b>	<b>U51290</b>	<b>ltr<sup>4</sup></b>	<b>Oct. 4, 1996</b>
<b>14</b>	<b>93BR029.4</b>	<b>AF005495</b>	<b>complete</b>	<b>May 7, 1998</b>
<b>15</b>	<b>93BR029.2</b>	<b>U27413</b>	<b>env and nef genes, partial cds</b>	<b>Aug. 19, 1996</b>
<b>16</b>	<b>93BR029</b>	<b>U51291</b>	<b>ltr region</b>	<b>Oct. 4, 1996</b>
<b>17</b>	<b>90CF056.1</b>	<b>AF005496</b>	<b>complete</b>	<b>May 7, 1998</b>
<b>18</b>	<b>90CF056.1</b>	<b>L11497</b>	<b>env, V3 region</b>	<b>Oct. 26, 1993</b>

<sup>1</sup> This date is obtained from the "Date" entry of the GenBank database printout. Sometimes the "Comment" entry indicates an earlier publication date. See, e.g., the entry for GenBank Accession No. U08793.

<sup>2</sup> The entries concerning the complete (or near-complete) sequences of the invention are highlighted in bold.

<sup>3</sup> cds = coding sequence

<sup>4</sup> ltr = long terminal repeat